Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 March 2004, Vol. 103, No. 6, pp. 2325-2331.
Prepublished online as a Blood First Edition Paper on November 26, 2003; DOI 10.1182/blood-2003-09-3287.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-09-3287v1
103/6/2325    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loh, M. L.
Right arrow Articles by Shannon, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loh, M. L.
Right arrow Articles by Shannon, K. M.
Related Collections
Right arrow Hematopoiesis and Stem Cells
Right arrow Neoplasia
Right arrow Oncogenes and Tumor Suppressors
Right arrow Signal Transduction
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis

Mignon L. Loh, Shashaank Vattikuti, Suzanne Schubbert, Melissa G. Reynolds, Elaine Carlson, Kenneth H. Lieuw, Jennifer W. Cheng, Connie M. Lee, David Stokoe, Jeannette M. Bonifas, Nicole P. Curtiss, Jason Gotlib, Soheil Meshinchi, Michelle M. Le Beau, Peter D. Emanuel, and Kevin M. Shannon

From the Department of Pediatrics, University of California, San Francisco; Comprehensive Cancer Center, University of California, San Francisco; Program in Human Genetics, University of California, San Francisco; Cancer Research Institute, University of California, San Francisco; Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA; Department of Pediatrics, University of Washington, Seattle; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham.

The PTPN11 gene encodes SHP-2 (Src homology 2 domain–containing protein tyrosine Phosphatase), a nonreceptor tyrosine protein tyrosine phosphatase (PTPase) that relays signals from activated growth factor receptors to p21Ras (Ras) and other signaling molecules. Mutations in PTPN11 cause Noonan syndrome (NS), a developmental disorder characterized by cardiac and skeletal defects. NS is also associated with a spectrum of hematologic disorders, including juvenile myelomonocytic leukemia (JMML). To test the hypothesis that PTPN11 mutations might contribute to myeloid leukemogenesis, we screened the entire coding region for mutations in 51 JMML specimens and in selected exons from 60 patients with other myeloid malignancies. Missense mutations in PTPN11 were detected in 16 of 49 JMML specimens from patients without NS, but they were less common in other myeloid malignancies. RAS, NF1, and PTPN11 mutations are largely mutually exclusive in JMML, which suggests that mutant SHP-2 proteins deregulate myeloid growth through Ras. However, although Ba/F3 cells engineered to express leukemia-associated SHP-2 proteins cells showed enhanced growth factor–independent survival, biochemical analysis failed to demonstrate hyperactivation of the Ras effectors extracellular-regulated kinase (ERK) or Akt. We conclude that SHP-2 is an important cellular PTPase that is mutated in myeloid malignancies. Further investigation is required to clarify how these mutant proteins interact with Ras and other effectors to deregulate myeloid growth.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Mutated SHP and AML in leukemias
Gen-Sheng Feng
Blood 2004 103: 1982-1983. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
G.-M. Zou and A. Maitra
Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration
Mol. Cancer Ther., July 1, 2008; 7(7): 2012 - 2021.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Eminaga and A. M. Bennett
Noonan Syndrome-associated SHP-2/Ptpn11 Mutants Enhance SIRP{alpha} and PZR Tyrosyl Phosphorylation and Promote Adhesion-mediated ERK Activation
J. Biol. Chem., May 30, 2008; 283(22): 15328 - 15338.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. S. Braun and K. Shannon
Targeting Ras in Myeloid Leukemias
Clin. Cancer Res., April 15, 2008; 14(8): 2249 - 2252.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Ren, Z. Chen, L. Chen, N. T. Woods, G. W. Reuther, J. Q. Cheng, H.-g. Wang, and J. Wu
Shp2E76K Mutant Confers Cytokine-independent Survival of TF-1 Myeloid Cells by Up-regulating Bcl-XL
J. Biol. Chem., December 14, 2007; 282(50): 36463 - 36473.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Zhang, E. Diaz-Flores, G. Li, Z. Wang, Z. Kang, E. Haviernikova, S. Rowe, C.-K. Qu, W. Tse, K. M. Shannon, et al.
Abnormal hematopoiesis in Gab2 mutant mice
Blood, July 1, 2007; 110(1): 116 - 124.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Voena, C. Conte, C. Ambrogio, E. Boeri Erba, F. Boccalatte, S. Mohammed, O. N. Jensen, G. Palestro, G. Inghirami, and R. Chiarle
The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration
Cancer Res., May 1, 2007; 67(9): 4278 - 4286.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. J. Chan and G.-S. Feng
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
Blood, February 1, 2007; 109(3): 862 - 867.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Lindsey, W. Huang, H. Wang, E. Horvath, C. Zhu, and E. A. Eklund
Activation of SHP2 Protein-tyrosine Phosphatase Increases HoxA10-induced Repression of the Genes Encoding gp91PHOX and p67PHOX
J. Biol. Chem., January 26, 2007; 282(4): 2237 - 2249.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Chen, W.-M. Yu, H. Daino, H. E. Broxmeyer, B. J. Druker, and C.-K. Qu
SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl
Blood, January 15, 2007; 109(2): 778 - 785.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. S. Braun, J. A. Archard, J. A. G. Van Ziffle, D. A. Tuveson, T. E. Jacks, and K. Shannon
Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo
Blood, September 15, 2006; 108(6): 2041 - 2044.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
W. Huang, G. Saberwal, E. Horvath, C. Zhu, S. Lindsey, and E. A. Eklund
Leukemia-Associated, Constitutively Active Mutants of SHP2 Protein Tyrosine Phosphatase Inhibit NF1 Transcriptional Activation by the Interferon Consensus Sequence Binding Protein.
Mol. Cell. Biol., September 1, 2006; 26(17): 6311 - 6332.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Wang, Z. Li, R. Ding, G. D. Frank, T. Senbonmatsu, E. J. Landon, T. Inagami, and Z. J. Zhao
Antagonism or Synergism: ROLE OF TYROSINE PHOSPHATASES SHP-1 AND SHP-2 IN GROWTH FACTOR SIGNALING
J. Biol. Chem., August 4, 2006; 281(31): 21878 - 21883.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Charest, E. W. Wilker, M. E. McLaughlin, K. Lane, R. Gowda, S. Coven, K. McMahon, S. Kovach, Y. Feng, M. B. Yaffe, et al.
ROS Fusion Tyrosine Kinase Activates a SH2 Domain-Containing Phosphatase-2/Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Signaling Axis to Form Glioblastoma in Mice.
Cancer Res., August 1, 2006; 66(15): 7473 - 7481.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. I. Kontaridis, K. D. Swanson, F. S. David, D. Barford, and B. G. Neel
PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects
J. Biol. Chem., March 10, 2006; 281(10): 6785 - 6792.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W.-M. Yu, H. Daino, J. Chen, K. D. Bunting, and C.-K. Qu
Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling
J. Biol. Chem., March 3, 2006; 281(9): 5426 - 5434.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Yuan, W.-M. Yu, M. Xu, and C.-K. Qu
SHP-2 Phosphatase Regulates DNA Damage-induced Apoptosis and G2/M Arrest in Catalytically Dependent and Independent Manners, Respectively
J. Biol. Chem., December 30, 2005; 280(52): 42701 - 42706.
[Abstract] [Full Text] [PDF]


Home page
ASH ANNUAL MEETING ABSTRACTSHome page
S. Schubbert, M. Zenker, S. L. Rowe, S. Boll, C. Klein, I. van der Burgt, L. Musante, H. Nguyen, B. West, G. Bollag, et al.
Novel Germ Line Mutations in the KRAS2 Gene Cause Noonan Syndrome and Deregulate Hematopoietic Cell Growth.
Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 1602 - 1602.
[Abstract]


Home page
J. Med. Genet.Home page
A J Bauer and C A Stratakis
The lentiginoses: cutaneous markers of systemic disease and a window to new aspects of tumourigenesis
J. Med. Genet., November 1, 2005; 42(11): 801 - 810.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Xu, Y. Yu, S. Zheng, X. Zhao, Q. Dong, Z. He, Y. Liang, Q. Lu, Y. Fang, X. Gan, et al.
Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia
Blood, November 1, 2005; 106(9): 3142 - 3149.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M. K. Sharma, B. A. Zehnbauer, M. A. Watson, and D. H. Gutmann
RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma
Neurology, October 25, 2005; 65(8): 1335 - 1336.
[Full Text] [PDF]


Home page
BloodHome page
C. P. Kratz, C. M. Niemeyer, R. P. Castleberry, M. Cetin, E. Bergstrasser, P. D. Emanuel, H. Hasle, G. Kardos, C. Klein, S. Kojima, et al.
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease
Blood, September 15, 2005; 106(6): 2183 - 2185.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Keilhack, F. S. David, M. McGregor, L. C. Cantley, and B. G. Neel
Diverse Biochemical Properties of Shp2 Mutants: IMPLICATIONS FOR DISEASE PHENOTYPES
J. Biol. Chem., September 2, 2005; 280(35): 30984 - 30993.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Schubbert, K. Lieuw, S. L. Rowe, C. M. Lee, X. Li, M. L. Loh, D. W. Clapp, and K. M. Shannon
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells
Blood, July 1, 2005; 106(1): 311 - 317.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Illmer, C. Thiede, A. Fredersdorf, S. Stadler, A. Neubauer, G. Ehninger, and M. Schaich
Activation of the RAS Pathway Is Predictive for a Chemosensitive Phenotype of Acute Myelogenous Leukemia Blasts
Clin. Cancer Res., May 1, 2005; 11(9): 3217 - 3224.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. J. Chan, M. B. Leedy, V. Munugalavadla, C. S. Voorhorst, Y. Li, M. Yu, and R. Kapur
Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor
Blood, May 1, 2005; 105(9): 3737 - 3742.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Chen, M. Levis, P. Brown, K.-T. Kim, J. Allebach, and D. Small
FLT3/ITD Mutation Signaling Includes Suppression of SHP-1
J. Biol. Chem., February 18, 2005; 280(7): 5361 - 5369.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Bentires-Alj, J. G. Paez, F. S. David, H. Keilhack, B. Halmos, K. Naoki, J. M. Maris, A. Richardson, A. Bardelli, D. J. Sugarbaker, et al.
Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
Cancer Res., December 15, 2004; 64(24): 8816 - 8820.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Loh and K. M. Shannon
A "Ras-in-ALL" model of signaling?
Blood, July 15, 2004; 104(2): 297 - 298.
[Full Text] [PDF]


Home page
BloodHome page
M. Tartaglia, S. Martinelli, G. Cazzaniga, V. Cordeddu, I. Iavarone, M. Spinelli, C. Palmi, C. Carta, A. Pession, M. Arico, et al.
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia
Blood, July 15, 2004; 104(2): 307 - 313.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Yoshida, T. Hasegawa, Y. Hasegawa, T. Nagai, E. Kinoshita, Y. Tanaka, H. Kanegane, K. Ohyama, T. Onishi, K. Hanew, et al.
Protein-Tyrosine Phosphatase, Nonreceptor Type 11 Mutation Analysis and Clinical Assessment in 45 Patients with Noonan Syndrome
J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3359 - 3364.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
C.-H. Pui, M. Schrappe, R. C. Ribeiro, and C. M. Niemeyer
Childhood and Adolescent Lymphoid and Myeloid Leukemia
Hematology, January 1, 2004; 2004(1): 118 - 145.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020